Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$672M |
| 2 |
Merck
MRK
|
+$608M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$384M |
| 4 |
Las Vegas Sands
LVS
|
+$378M |
| 5 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$303M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ralph Lauren
RL
|
+$518M |
| 2 |
eBay
EBAY
|
+$474M |
| 3 |
Estee Lauder
EL
|
+$435M |
| 4 |
Goldman Sachs
GS
|
+$323M |
| 5 |
TechnipFMC
FTI
|
+$304M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.85% |
| 3 | Communication Services | 11.23% |
| 4 | Technology | 10.46% |
| 5 | Energy | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
RH
RH
$3.33B
| $23.7M | 0.02% |
321,601
-3,764
| -1% | -$235K |
|
427
PUT
BioMarin Pharmaceuticals
BMRN
$11.9B
| $23.6M | 0.02% |
+345,600
| New | +$25.5M |
|
|
PPO
428
DELISTED
POLYPORE INTERNATIONAL, INC
PPO
| $23.3M | 0.02% |
680,333
-389,090
| -36% | -$13.6M |
|
429
Tandem Diabetes Care
TNDM
$1.27B
| $23M | 0.02% |
104,247
+9,805
| +10% | +$2.5M |
|
|
ZU
430
DELISTED
ZULILY INC CLASS A COMMON STOCK
ZU
| $22.9M | 0.02% |
456,649
+108,388
| +31% | +$5.23M |
|
431
PTC Therapeutics
PTCT
$6.18B
| $22.5M | 0.02% |
861,826
-164,091
| -16% | -$4.41M |
|
432
RBC Bearings
RBC
$17.4B
| $22.2M | 0.02% |
348,971
-435,570
| -56% | -$28.5M |
|
433
BOK Financial
BOKF
$8.58B
| $22.1M | 0.02% |
319,873
-5,389
| -2% | -$353K |
|
434
Conagra Brands
CAG
$7.42B
| $21.8M | 0.02% |
+903,651
| New | +$21.7M |
|
|
CHC
435
DELISTED
CHINA HYDROELECTRIC CORP SPONSORED ADR RPSTG 3 ORD SHS
CHC
| $21.4M | 0.02% |
6,303,216
-232,755
| -4% | -$768K |
|
|
CLDT
436
Chatham Lodging
CLDT
$632M
| $21.1M | 0.02% |
1,042,115
-25,545
| -2% | -$525K |
|
|
CMO
437
DELISTED
Capstead Mortgage Corp.
CMO
| $21M | 0.02% |
1,659,734
+135,315
| +9% | +$1.71M |
|
438
Southern Copper
SCCO
$138B
| $20.7M | 0.02% |
767,330
-20,895
| -3% | -$562K |
|
|
CIM
439
Chimera Investment
CIM
$1.06B
| $20.6M | 0.02% |
449,425
+24,386
| +6% | +$1.13M |
|
|
CYT
440
DELISTED
CYTEC INDS INC
CYT
| $20.5M | 0.02% |
+419,784
| New | +$19.5M |
|
|
AVDL
441
DELISTED
Avadel Pharmaceuticals
AVDL
| $20.1M | 0.02% |
+1,500,000
| New | +$16.1M |
|
|
HELI
442
DELISTED
CHC GROUP LTD SHS NEW (CYM)
HELI
| $20.1M | 0.02% |
+90,655
| New | +$24.2M |
|
|
SUSS
443
DELISTED
SUSSER HOLDINGS CORPORATION COMMON STOCK
SUSS
| $19.5M | 0.02% |
311,685
-17,885
| -5% | -$1.1M |
|
|
RP
444
DELISTED
RealPage, Inc.
RP
| $19.5M | 0.02% |
1,071,191
+17,676
| +2% | +$355K |
|
|
LMOS
445
DELISTED
Lumos Networks Corp
LMOS
| $19.2M | 0.02% |
1,436,856
-8,957
| -0.6% | -$153K |
|
|
PTLA
446
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $18.6M | 0.02% |
717,216
-353,864
| -33% | -$9.44M |
|
|
ORBC
447
DELISTED
ORBCOMM, Inc.
ORBC
| $18.2M | 0.02% |
2,658,705
+377,105
| +17% | +$2.71M |
|
448
PUT
Vertex Pharmaceuticals
VRTX
$123B
| $17.7M | 0.02% |
+250,000
| New | +$19.8M |
|
|
HMHC
449
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $17.6M | 0.02% |
864,742
-1,297,246
| -60% | -$24.9M |
|
|
FEIC
450
DELISTED
FEI COMPANY
FEIC
| $17.3M | 0.02% |
+167,909
| New | +$16.5M |
|
Similar funds
Jennison Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Jennison Associates held 826 positions worth $105B, up 2.6% from $102B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jennison Associates's Q1 2014 filing shows 122 new, 275 increased, 321 reduced and 94 closed positions. Its largest new stake was Perrigo: 4,257,843 shares worth $659M. The largest sale was Ralph Lauren, an estimated $518M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q1 2014 buy was Perrigo: 4,257,843 shares worth $659M.
- Jennison Associates added most to Merck in Q1 2014, an estimated $608M increase.
- Jennison Associates's biggest Q1 2014 reduction was Estee Lauder, cutting an estimated $435M.
- Jennison Associates fully exited Ralph Lauren in Q1 2014, selling an estimated $518M.
- Jennison Associates's ten largest holdings make up 18% of its $105B portfolio in Q1 2014.
- Jennison Associates opened 122 new positions and closed 94 in Q1 2014.
- Jennison Associates's portfolio value rose 2.6% quarter-over-quarter to $105B.
Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.